» Authors » Jason Cassaday

Jason Cassaday

Explore the profile of Jason Cassaday including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 18
Citations 95
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang J, Cassaday J, Wyche T, Squadroni B, Newhard W, Trinh H, et al.
Biotechnol Bioeng . 2024 May; 121(9):2691-2705. PMID: 38715197
The human microbiota impacts a variety of diseases and responses to therapeutics. Due to a lack of robust in vitro models, detailed mechanistic explanations of host-microbiota interactions cannot often be...
2.
Wei J, Radcliffe S, Pirrone A, Lu M, Li Y, Cassaday J, et al.
Viruses . 2023 Oct; 15(10). PMID: 37896813
Despite the success of rotavirus vaccines, rotaviruses remain one of the leading causes of diarrheal diseases, resulting in significant childhood morbidity and mortality, especially in low- and middle-income countries. The...
3.
Kasper S, Otten S, Squadroni B, Orr-Terry C, Kuang Y, Mussallem L, et al.
Bioeng Transl Med . 2023 Sep; 8(5):e10542. PMID: 37693049
Cyclic peptides are poised to target historically difficult to drug intracellular protein-protein interactions, however, their general cell impermeability poses a challenge for characterizing function. Recent advances in microfluidics have enabled...
4.
Squadroni B, Newhard W, Carr D, Trinh H, Racine F, Zuck P, et al.
SLAS Technol . 2022 Apr; 27(4):247-252. PMID: 35367399
Dynamic in vitro antibacterial studies provide valuable insight on effective dosing strategies prior to translating to in vivo models. Frequent sampling is required to monitor the pharmacodynamics (PD) of these...
5.
Newhard W, Patel M, Cassaday J, Ballard J, Squadroni B, Wu G, et al.
SLAS Discov . 2021 Jan; 26(5):642-654. PMID: 33427012
Antiretroviral therapy is able to effectively control but not eradicate HIV infection, which can persist, leading to the need for lifelong therapy. The existence of latently HIV-infected cells is a...
6.
Homsher M, Beshore D, Cassaday J, Squadroni B, Mohammed E, Hartnett M, et al.
SLAS Discov . 2017 Apr; 22(8):1060-1066. PMID: 28426939
Agonist shift assays feature cross-titrations of allosteric modulators and orthosteric ligands. Information generated in agonist shift assays can include a modulator's effect on the orthosteric agonist's potency (alpha) and efficacy...
7.
Nothstein J, MacColl E, Zuck P, Cassaday J, Uebele V, Hermes J, et al.
SLAS Technol . 2016 Dec; 22(5):485-492. PMID: 28027447
Automated mechanism of action studies are introducing the need for tailored compound delivery, which can be challenging for standard compound management procedures. Jump dilution assays investigating inhibitor reversibility require compound...
8.
Cassaday J, Finley M, Squadroni B, Jezequel-Sur S, Rauch A, Gajera B, et al.
SLAS Technol . 2016 Nov; 22(2):195-205. PMID: 27864339
In the triage of hits from a high-throughput screening campaign or during the optimization of a lead compound, it is relatively routine to test compounds at multiple concentrations to determine...
9.
Finley M, Cassaday J, Kreamer T, Li X, Solly K, ODonnell G, et al.
J Biomol Screen . 2016 Feb; 21(5):480-9. PMID: 26861708
The NaV1.7 voltage-gated sodium channel is a highly valued target for the treatment of neuropathic pain due to its expression in pain-sensing neurons and human genetic mutations in the gene...
10.
Tanaka K, Koresawa M, Iida M, Fukasawa K, Stec E, Cassaday J, et al.
Assay Drug Dev Technol . 2010 Jan; 8(1):47-62. PMID: 20085455
One of the challenges to develop time-resolved fluorescence resonance energy transfer (TR-FRET) assay for serine/threonine (Ser/Thr) protein kinase is to select an optimal peptide substrate and a specific phosphor Ser/Thr...